Mary Wilson
Well-known member
The TB/COVID-19 Global Study Group
Eur Respir J 2021; in press (https://doi.org/10.1183/13993003.02538-2021).
Abstract
Information on tuberculosis (TB) and COVID-19 is still limited.
The aim of this study is to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multi-country register-based cohort with special focus on the determinants of mortality and other outcomes.
We enrolled all patients of any age with either active TB or previous TB and COVID-19.
172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (>50% population-based).
Of 767 patients, 553/747 (74.0 %) had TB before COVID-19 (including 234/747 with previous TB), 71/747 (9.5%) had COVID-19 first and 123/747 (16.5%) had both diseases diagnosed within the same week (35, 4.6% on the same day).
85/767 patients died (11.08%) (41/289 (14.2%) in Europe and 44/478 (9.2%) outside Europe; (P=0.03)): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, 1/85 (1.2%) from TB and 11 from other causes.
In the univariate analysis on mortality the following variables reached statistical significance: age, being male, having >1 comorbidity; diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender, and invasive ventilation as independent contributors to mortality.
The data suggests TB and COVID-19 are a ‘cursed duet’ and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination.
https://erj.ersjournals.com/content/erj/early/2021/11/04/13993003.02538-2021.full.pdf
Eur Respir J 2021; in press (https://doi.org/10.1183/13993003.02538-2021).
Abstract
Information on tuberculosis (TB) and COVID-19 is still limited.
The aim of this study is to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multi-country register-based cohort with special focus on the determinants of mortality and other outcomes.
We enrolled all patients of any age with either active TB or previous TB and COVID-19.
172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (>50% population-based).
Of 767 patients, 553/747 (74.0 %) had TB before COVID-19 (including 234/747 with previous TB), 71/747 (9.5%) had COVID-19 first and 123/747 (16.5%) had both diseases diagnosed within the same week (35, 4.6% on the same day).
85/767 patients died (11.08%) (41/289 (14.2%) in Europe and 44/478 (9.2%) outside Europe; (P=0.03)): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, 1/85 (1.2%) from TB and 11 from other causes.
In the univariate analysis on mortality the following variables reached statistical significance: age, being male, having >1 comorbidity; diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender, and invasive ventilation as independent contributors to mortality.
The data suggests TB and COVID-19 are a ‘cursed duet’ and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination.
https://erj.ersjournals.com/content/erj/early/2021/11/04/13993003.02538-2021.full.pdf